Bruton Tyrosine Kinase Inhibitors in Leukemia and Lymphoma

Callie Coombs, MD, and Brian Koffman, MD, provide an overview of chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma, and explore the key differences between these disease states.

Brian Koffman, MD, and Callie Coombs, MD, provide the prevalence and incidence rates of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and small lymphocytic lymphoma (SLL), and describe how the diagnosis and management of CLL/MCL/SLL impacts a patient’s quality of life.

A panel of experts discuss the most important goals of therapy for patients with chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma and the largest unmet needs in leukemia/lymphoma.

Callie Coombs, MD, discusses recent changes you have seen in the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and small lymphocytic lymphoma (SLL) and provides an overview of the Bruton tyrosine kinase inhibitor landscape for CLL, MCL, and SLL.

A panel of experts discuss the provider, payer, and patient challenges that must be considered with BTK inhibitors in chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma.

Brian Koffman, MD, reviews how Bruton tyrosine kinase inhibitors are addressing unmet needs in chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma, and what unmet needs remain.

Callie Coombs, MD, discusses how pirtobrutinib (LOXO-305), a Bruton tyrosine kinase inhibitor (BTKi) being investigated in the BRUIN trial, might impact the BTKi landscape.

Roy Beveridge, MD, discusses how payers and health systems are managing Bruton tyrosine kinase inhibitors and how they are chosen for formulary and pathway coverage.

Callie Coombs, MD, reviews how patients develop resistance to Bruton Tyrosine Kinase inhibitor (BTKi) therapy and how BTKi resistance is managed.

Brian Koffman, MD, and Roy Beveridge, MD, discuss the financial burdens of Bruton tyrosine kinase inhibitor therapy and considerations for oral therapy vs infusion therapy.

Roy Beveridge, MD, and Brian Koffman, MD, explore how the Bruton tyrosine kinase inhibitors (BTKi) fit into value-based care models for oncology and the patient support offered to aid patients in gaining access to BTKis.

Callie Coombs, MD, and Roy Beveridge, MD, discuss the education needed for payers and physicians surrounding the use of the Bruton tyrosine kinase inhibitors.

The panel of experts provide their closing thoughts on the burden of disease in leukemia and lymphoma and the Bruton tyrosine kinase inhibitor landscape.